BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/480/0.1/21.06.24 | Market Closed - Boerse Frankfurt Warrants 19:03:33 07/06/2024 BST | ||
| 1.14 EUR | +11.76% |
|
| Current month | +440.28% | ||
| 1 month | +3,700.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 1.14 | +11.76% |
| 06/06/24 | 1.02 | -12.82% |
| 05/06/24 | 1.17 | +69.57% |
| 04/06/24 | 0.69 | +30.19% |
| 03/06/24 | 0.53 | +151.18% |
Real-time Boerse Frankfurt Warrants
Last update June 07, 2024 at 07:03 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM729U |
| ISIN | DE000VM729U2 |
| Date issued | 05/01/2024 |
| Strike | 480 $ |
| Maturity | 21/06/2024 (14 Days) |
| Parity | 10 : 1 |
| Emission price | 1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.98 € |
|---|---|
| Lowest since issue | 0.026 € |
| Spread | 0.04 € |
| Spread % | 3.64% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Warrants
- Warrant